Literature DB >> 3338874

Biological characterization and oncogene expression in human colorectal carcinoma cell lines.

D L Trainer1, T Kline, F L McCabe, L F Faucette, J Feild, M Chaikin, M Anzano, D Rieman, S Hoffstein, D J Li.   

Abstract

To establish well-characterized cellular reagents for the study of colon carcinoma, we have examined 19 human colorectal carcinoma cell lines with regard to morphology, ultrastructure, expression of tumor-associated antigens, proliferative capacity in vitro, anchorage-independent growth, oncogene expression, tumorigenicity and malignant potential. Cell lines examined were cultured under identical conditions, and in vitro and in vivo analyses were performed in parallel on replicate cultures. Three classes of colorectal cell lines were defined according to their tumorigenicity in nude mice. Class-1 lines formed rapidly progressing tumors in nearly all mice at an inoculum of 10(6) cells. Cell lines belonging to class-2 were less tumorigenic, producing tumors later and at a slower growth rate. Class-3 lines were non-tumorigenic under all experimental conditions tested. By Northern analysis, the oncogenes c-myc, H-ras, K-ras, N-ras, myb, fos and p53 were expressed in nearly all cell lines examined. In contrast, transcripts for abl, src and ros were not detected. The best in vitro predictor of tumorigenicity was colony formation in soft agar. There was no detectable correlation between tumorigenicity and metastatic potential, doubling time in vitro, production of tumor-associated markers, xenograft histology or expression of specific oncogenes.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3338874     DOI: 10.1002/ijc.2910410221

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  50 in total

1.  Differential sensitivity of human epithelial cells to Pseudomonas aeruginosa exoenzyme S.

Authors:  E M McGuffie; J E Fraylick; D J Hazen-Martin; T S Vincent; J C Olson
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

2.  A modified Boyden chamber assay for tumor cell transendothelial migration in vitro.

Authors:  Y H Li; C Zhu
Journal:  Clin Exp Metastasis       Date:  1999-07       Impact factor: 5.150

3.  A new human colon carcinoma line.

Authors:  W Liebrich; S Gonser; S Brüderlein; P Schlag
Journal:  In Vitro Cell Dev Biol       Date:  1991-05

4.  Oxidovanadium(IV) complexes with chrysin and silibinin: anticancer activity and mechanisms of action in a human colon adenocarcinoma model.

Authors:  I E León; J F Cadavid-Vargas; I Tiscornia; V Porro; S Castelli; P Katkar; A Desideri; M Bollati-Fogolin; S B Etcheverry
Journal:  J Biol Inorg Chem       Date:  2015-09-24       Impact factor: 3.358

5.  A novel reporter system for molecular imaging and high-throughput screening of anticancer drugs.

Authors:  Jingping Xie; Chunxia Wang; John Virostko; H Charles Manning; Wellington Pham; Joshua Bauer; John C Gore
Journal:  Chembiochem       Date:  2013-07-24       Impact factor: 3.164

6.  IMP1 3' UTR shortening enhances metastatic burden in colorectal cancer.

Authors:  Sarah F Andres; Kathy N Williams; Jacqueline B Plesset; Jeffrey J Headd; Rei Mizuno; Priya Chatterji; Ashley A Lento; Andres J Klein-Szanto; Rosemarie Mick; Kathryn E Hamilton; Anil K Rustgi
Journal:  Carcinogenesis       Date:  2019-06-10       Impact factor: 4.944

7.  Application of genomic principles to pharmacotherapy of cancer.

Authors:  Christopher L Farrell; Nancy G Pedigo; Amy R Messersmith
Journal:  Am J Pharm Educ       Date:  2014-04-17       Impact factor: 2.047

8.  mTOR-independent 4E-BP1 phosphorylation is associated with cancer resistance to mTOR kinase inhibitors.

Authors:  Yanjie Zhang; X F Steven Zheng
Journal:  Cell Cycle       Date:  2012-02-01       Impact factor: 4.534

9.  Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells.

Authors:  R Riesenberg; R Oberneder; M Kriegmair; M Epp; U Bitzer; A Hofstetter; S Braun; G Riethmüller; K Pantel
Journal:  Histochemistry       Date:  1993-01

10.  The serine protease inhibitor serpinE2 is a novel target of ERK signaling involved in human colorectal tumorigenesis.

Authors:  Sébastien Bergeron; Etienne Lemieux; Véronique Durand; Sébastien Cagnol; Julie C Carrier; Jacques G Lussier; Marie-Josée Boucher; Nathalie Rivard
Journal:  Mol Cancer       Date:  2010-10-13       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.